Progress in the treatment with dopamine receptor agonist-induced impulse control disorders

doi:10.16352/j.issn.1001-6325.2022.09.1433

Abstract

Abstract: It is found that patients with hyperprolactinemia may have impulse control disorder(ICD) when treated with dopamine receptor agonist(DA), such as pathological gambling, high sexual desire, high appetite and forced shopping. This phenomenon also occurs in patients with Parkinson's disease (PD) or other neurological diseases treated with dopamine agonists. The pathogenesis may be that DA overstimulates D3 receptor. Drug withdrawal is a well accepted treatment method, which may reach a better catabatic outcome.

Key words: impulse control disorder, dopamine receptor agonist, hyperprolactinemia

CLC Number:

R584.1

ZHANG Rui, WU Xue-yan. Progress in the treatment with dopamine receptor agonist-induced impulse control disorders[J]. Basic & Clinical Medicine, 2022, 42(9): 1433-1437.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/10.16352/j.issn.1001-6325.2022.09.1433

http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/Y2022/V42/I9/1433

References 28

[1]	Beccuti G, Guaraldi F, Natta G, et al. Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study[J]. J Endocrinol Invest,2020. doi: 10.1007/s40618-020-01478-0.
[2]	Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs[J]. JAMA Intern Med,2014,174:1930-1933.
[3]	Davie M. Pathological gambling associated with cabergol-ine therapy in a patient with a pituitary prolactinoma[J]. J Neuropsychiatry Clin Neurosci. Fall, 2007,19:473-474.
[4]	Hinojosa-Amaya JM, Johnson N, González-Torres C, et al. Depression and impulsivity self-assessment tools to identify dopamine agonist side effects in patients with pituitary adenomas[J]. Front Endocrinol (Lausanne),2020,11:579606. doi: 10.3389/fendo.2020.579606.
[5]	Lin YP, Liang HY, Chen YS, et al. Objective assessment of impulse control disorder in patients with Parkinson's disease using a low-cost LEGO-like EEG headset: a feasibility study[J]. J Neuroeng Rehabil,2021,18:109. doi: 10.1186/s12984-021-00897-1.
[6]	Drew DS, Muhammed K, Baig F, et al. Dopamine and reward hypersensitivity in Parkinson's disease with impulse control disorder[J]. Brain,2020,143:2502-2518.
[7]	Klein MO, Battagello DS, Cardoso AR, et al. Dopamine: functions, signaling, and association with neurological diseases[J]. Cell Mol Neurobiol,2019,39:31-59.
[8]	Celik E, Ozkaya HM, Poyraz BC, et al. Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up[J]. Endocrine,2018,62:692-700.
[9]	Dogansen SC, Cikrikcili U, Oruk G, et al. Dopamine agonist-induced impulse control disorders in patients with prolactinoma: a cross-sectional multicenter study[J]. J Clin Endocrinol Metab,2019,104:2527-2534.
[10]	Beccuti G, Guaraldi F, Natta G, et al. Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study[J]. J Endocrinol Invest, 2021,44:1699-1706.
[11]	De Sousa SMC, Baranoff J, Rushworth RL, et al. Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors[J]. J Clin Endocrinol Metab,2020,105. doi: 10.1210/clinem/dgz076.
[12]	Ozkaya HM, Sahin S, Korkmaz OP, et al. Patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas[J]. Growth Horm IGF Res,2020,55:101356. doi: 10.1016/j.ghir.2020.101356.
[13]	Kon T, Ueno T, Haga R, et al. The factors associated with impulse control behaviors in Parkinson's disease: a 2-year longitudinal retrospective cohort study[J]. Brain Behav,2018,8:e01036. doi: 10.1002/brb3.1036.
[14]	Fantini ML, Figorilli M, Arnulf I, et al. Sleep and REM sleep behaviour disorder in Parkinson's disease with impulse control disorder[J]. J Neurol Neurosurg Psychiatry,2018,89:305-310.
[15]	Corvol JC, Artaud F, Cormier-Dequaire F, et al. Longitudinal analysis of impulse control disorders in Parkinson disease[J]. Neurology,2018,91:e189-e201. doi: 10.1212/wnl.0000000000005816.
[16]	Bastiaens J, Dorfman BJ, Christos PJ, et al. Prospective cohort study of impulse control disorders in Parkinson's disease[J]. Mov Disord,2013,28:327-333.
[17]	Martinez-Martin P, Wan YM, Ray Chaudhuri K, et al. Impulse control and related behaviors in Parkinson's disease with dementia[J]. Eur J Neurol,2020,27:944-950.
[18]	Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline[J]. J Clin Endocrinol Metab,2011,96:273-288.
[19]	Matsuda N, Kobayashi S, Ugawa Y. Devotion to painting in a Parkinson's disease patient[J]. Rinsho Shinkeigaku,2018,58:756-760.
[20]	Seeman P. Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors[J]. Synapse,2015,69:183-189.
[21]	Wolfschlag M, Hkansson A. Increased risk for develop-ing gambling disorder under the treatment with prami-pexole, ropinirole, and aripiprazole: a nationwide register study in Sweden[J]. PLoS One, 2021,16:e0252516. doi: 10.1371/journal.pone.0252516.
[22]	Gallagher DA, O'Sullivan SS, Evans AH, et al. Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series[J]. Mov Disord,2007,22:1757-1763.
[23]	Ioachimescu AG, Fleseriu M, Hoffman AR, et al. Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas[J]. Eur J Endocrinol,2019,180:31-40.
[24]	Allard L, Albarel F, Bertherat J, et al. Efficacy and safety of dopamine agonists in patients treated with antipsychotics and presenting a macroprolactinoma[J]. Eur J Endocrinol, 2020,183:221-231.
[25]	Lee JY, Jeon B, Koh SB, et al. Behavioural and trait changes in parkinsonian patients with impulse control disorder after switching from dopamine agonist to levodopa therapy: results of REIN-PD trial[J]. J Neurol Neurosurg Psychiatry,2019,90:30-37.
[26]	Kim A, Kim YE, Kim HJ, et al. A 7-year observation of the effect of subthalamic deep brain stimulation on impulse control disorder in patients with Parkinson's disease[J]. Parkinsonism Relat Disord, 2018,56:3-8.
[27]	Rodríguez-Violante M, Ríos-Solís Y, Esquivel-Zapata O, et al. Assessment of therapeutic strategies for management of impulse control disorder in Parkinson's disease[J]. Arq Neuropsiquiatr, 2021,79:989-994.
[28]	De Sousa SM, Chapman IM, Falhammar H, et al. Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists[J]. Endocrine, 2017,55:618-624.